<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01794208</url>
  </required_header>
  <id_info>
    <org_study_id>GEXGP24201</org_study_id>
    <nct_id>NCT01794208</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of FSH-GEX™ in Comparison With 150 IU Gonal-f®</brief_title>
  <official_title>A Phase II, Multicentre, Multinational, Randomised, Assessor-Blind Trial to Investigate the Efficacy and Safety of Various Dosages of FSH-GEX™ in Comparison With 150 IU Gonal-f® in Women Undergoing ICSI Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Glycotope GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Glycotope GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the current study was the determination of the recommended standard treatment dose&#xD;
      of FSH-GEX(TM) in women undergoing intracytoplasmic sperm injection (ICSI) treatment as&#xD;
      assessed by follicle growth.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a phase II, randomized, assessor-blind, comparator-controlled, multiple dose study&#xD;
      in women undergoing ICSI treatment.&#xD;
&#xD;
      The primary objective of the study was the determination of the recommended standard&#xD;
      treatment dose of FSH-GEX™ as assessed by follicle growth dynamics in women between 18 and 37&#xD;
      years of age who were undergoing intracytoplasmic sperm injection treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 8, 2013</start_date>
  <completion_date type="Actual">July 30, 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of follicles</measure>
    <time_frame>day of hCG injection; variable timeframe; up to 18 days for maximum</time_frame>
    <description>The number of follicles with a diameter of ≥ 12 mm on the day of human chorionic gonadotropin (hCG) injection after stimulation with follicle stimulating hormone (FSH)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Follicular response</measure>
    <time_frame>every second day up to hCG injection; variable timeframe; up to 18 days for maximum</time_frame>
    <description>For each ovary the number of follicles were classified and summarised as follows: mean diameter 8.0 - 9.9 mm, 10.0 - 11.9 mm, 12.0 - 13.9 mm, 14.0 - 15.9 mm, 16.0 - 17.9 mm, 18.0 - 19.9 mm, and &gt;19.9 mm as determined by transvaginal ultrasonography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulus-oocyte-complexes</measure>
    <time_frame>at oocyte retrieval; 32 - 36 hours after hCG injection</time_frame>
    <description>Number of retrieved cumulus-oocyte-complexes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oocytes retrieved</measure>
    <time_frame>at oocyte retrieval; 32 - 36 hours after hCG injection</time_frame>
    <description>Number of oocytes retrieved (metaphase II)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Two pronuclei oocytes</measure>
    <time_frame>one day after oocyte retrieval</time_frame>
    <description>Number of two pronuclei (2PN) oocytes one day after follicle puncture</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical pregnancy rate</measure>
    <time_frame>14 to 20 days after oocyte retrieval</time_frame>
    <description>Based on positive β-hCG pregnancy test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical pregnancy rate</measure>
    <time_frame>approx. 4 to 6 weeks after last FSH dose</time_frame>
    <description>Based on clinical or ultrasound parameters (gestational sac, foetal heart beat</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Implantation rate</measure>
    <time_frame>approx. 4 to 6 weeks after last FSH dose</time_frame>
    <description>Number of foetal sacs on sonography divided by number of embryos transferred per embryo transfer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estradiol and inhibin B serum levels</measure>
    <time_frame>every second day up to hCG injection; variable timeframe; up to 18 days maximum</time_frame>
    <description>Concentration of Estradiol and Inhibin B in Serum after FSH stimulation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events, ovarian hyperstimulation syndrome, anti-drug-antibodies, overall tolerability</measure>
    <time_frame>up to 4 to 6 weeks after last FSH dose</time_frame>
    <description>Incidence of adverse events, ovarian hyperstimulation syndrome, anti-drug-antibodies, overall tolerability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of doses and total dose of FSH</measure>
    <time_frame>variable timeframe; up to 18 days for maximum</time_frame>
    <description>The total dose is the amount of FSH-GEX(TM) or Gonal-f® administered to each patient during the stimulation period</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Ongoing pregnancy rate</measure>
    <time_frame>10 weeks after gestation</time_frame>
    <description>A pregnancy is considered an ongoing pregnancy if pregnancy can be confirmed for more than 10 weeks after gestation.</description>
  </other_outcome>
  <other_outcome>
    <measure>Life birth rate</measure>
    <time_frame>up to nine month after embryo transfer</time_frame>
    <description>The live birth rate will be calculated as the total number of live births divided by the number of randomised patients</description>
  </other_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">267</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>treatment 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Follitropin Epsilon 52.5 IU quaque die (QD) s.c.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>treatment 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Follitropin Epsilon 75 IU QD s.c.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>treatment 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Follitropin Epsilon 112.5 IU QD s.c.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>treatment 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Follitropin Epsilon 150 IU QD s.c.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>treatment 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Follitropin Epsilon 150 IU quaque altera die (QAD) s.c.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>treatment 6</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Follitropin alfa 150 IU QD s.c.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Follitropin Epsilon</intervention_name>
    <arm_group_label>treatment 1</arm_group_label>
    <arm_group_label>treatment 2</arm_group_label>
    <arm_group_label>treatment 3</arm_group_label>
    <arm_group_label>treatment 4</arm_group_label>
    <arm_group_label>treatment 5</arm_group_label>
    <other_name>FSH-GEX(TM)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Follitropin Alfa</intervention_name>
    <arm_group_label>treatment 6</arm_group_label>
    <other_name>Gonal-f(R)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female patient for whom ICSI treatment is justified&#xD;
&#xD;
          -  Serum follicle-stimulating hormone concentration&#xD;
&#xD;
          -  Anti-mullerian hormone concentration&#xD;
&#xD;
          -  Antral follicle count&#xD;
&#xD;
          -  Body mass index and body weight&#xD;
&#xD;
          -  Presence of both ovaries&#xD;
&#xD;
          -  Regular spontaneous cycles between 21 and 35 days in length&#xD;
&#xD;
          -  Normal uterine cavity as assessed by transvaginal sonography at Screening&#xD;
&#xD;
          -  Willing and able to comply with the protocol&#xD;
&#xD;
          -  Willing and able to provide written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who had more than two unsuccessful previous assisted reproduction technology&#xD;
             cycles before inclusion into the study&#xD;
&#xD;
          -  Previous poor responders&#xD;
&#xD;
          -  Patients with previous hyperstimulation syndrome or cycle cancellation because of&#xD;
             imminent hyperstimulation syndrome&#xD;
&#xD;
          -  Patients with a history of or current polycystic ovarian morphology syndrome&#xD;
&#xD;
          -  Patients with a history of or current endometriosis III or IV&#xD;
&#xD;
          -  Presence of ovarian cyst at Screening&#xD;
&#xD;
          -  Any contraindication to becoming pregnant&#xD;
&#xD;
          -  History of ≥ 3 clinical or preclinical miscarriages&#xD;
&#xD;
          -  Abnormal cervical smear, Papanicolaou [PAP] score ≥ 3&#xD;
&#xD;
          -  Any history of malignant cancer other than in situ breast or skin cancer requiring&#xD;
             local excision&#xD;
&#xD;
          -  Any endocrine abnormalities requiring treatment&#xD;
&#xD;
          -  Any clinically significant systematic disease&#xD;
&#xD;
          -  Any known infection with human immunodeficiency virus, hepatitis B or C&#xD;
&#xD;
          -  History of thrombosis or other risk factors including any coagulation abnormality&#xD;
             leading to an increased risk of clotting&#xD;
&#xD;
          -  Family history of genetic risk factors concerning pregnancy or birth&#xD;
&#xD;
          -  Use of concomitant medication, which in the opinion of the investigator might&#xD;
             interfere with ICSI preparation procedures&#xD;
&#xD;
          -  Active smoking&#xD;
&#xD;
          -  Any active substance abuse of drugs, medications or alcohol within the last five years&#xD;
&#xD;
          -  Patients in an institution by official or court order&#xD;
&#xD;
          -  Patients who are unable or unwilling to provide informed consent&#xD;
&#xD;
          -  Any participation in another clinical trial within the last 60 days before&#xD;
             randomisation&#xD;
&#xD;
          -  Previous FSH-GEX™ administration.&#xD;
&#xD;
          -  Known hypersensitivity to any component of the investigational and non investigational&#xD;
             products used in this study&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>37 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Glycotope GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Glycotope Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glycotope Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>14050</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glycotope Investigational Medical Director</name>
      <address>
        <city>Bielefeld</city>
        <zip>33619</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glycotope Investigational Site</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40219</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glycotope Investigational Site</name>
      <address>
        <city>Heidelberg</city>
        <zip>69115</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glycotope Investigational Site</name>
      <address>
        <city>Lübeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glycotope Investigational Site</name>
      <address>
        <city>Budapest</city>
        <zip>1125</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glycotope Investigational Site</name>
      <address>
        <city>Tapolca</city>
        <zip>8300</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Hungary</country>
  </location_countries>
  <results_reference>
    <citation>Griesinger G, Dietrich B, Stöckl L, Eckert K, Goletz S, Tandler-Schneider A. Fully human glyco-optimized recombinant FSH (follitropin epsilon) - a randomized, comparator-controlled phase II clinical trial. Reprod Biomed Online. 2020 Feb;40(2):331-341. doi: 10.1016/j.rbmo.2019.09.003. Epub 2019 Sep 16.</citation>
    <PMID>31982355</PMID>
  </results_reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>January 23, 2013</study_first_submitted>
  <study_first_submitted_qc>February 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2013</study_first_posted>
  <last_update_submitted>May 4, 2021</last_update_submitted>
  <last_update_submitted_qc>May 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>in-vitro fertilization</keyword>
  <keyword>reproductive disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Follicle Stimulating Hormone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

